Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

Food Allergy Clinical Trial

— MILES  

Official title:

A Double-Blind, Placebo-Controlled Randomized Trial to Study the Viaskin Milk Efficacy and Safety for Treating IgE-Mediated Cow's Milk Allergy in Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02223182
• Other study ID #: MILES
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 2014
• Est. completion date: December 22, 2020

Study information

• Verified date: February 2021
• Source: DBV Technologies
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objectives of this study are to evaluate the safety and efficacy of Viaskin Milk after 12 months of epicutaneous immunotherapy (EPIT) treatment, for desensitizing IgE-mediated cow's milk allergic children and to assess the long-term safety and therapeutic benefit with Viaskin Milk.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 198
• Est. completion date: December 22, 2020
• Est. primary completion date: December 14, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 17 Years

Eligibility

Eligibility criteria for study enrollment:

Inclusion Criteria:

• Signed Informed Consent Form (ICF) by parent(s)/guardian(s) of subjects and informed assent form (IAF) for subjects =7 years, or as per local or country specific guidelines or regulations.

• Male or female subjects 2 to 17 years old at Visit 1.

• Documented medical history or physician-confirmed diagnosis of IgE-mediated CMA with systemic symptoms related to ingestion of milk or dairy products.

• Subjects currently following a strict cow's milk-free diet, with no consumption of dairy or baked milk products.

• Cow's milk-specific IgE level at screening =10 kU/L

• Positive Skin Prick Test (SPT) to cow's milk with a largest wheal diameter =6 mm.

• Positive DBPCFC at screening with an eliciting dose =300 mg cow's milk proteins (approximately =9.4 mL of cow's milk).

• Negative urine pregnancy test for female subjects of childbearing potential. Female subjects of childbearing potential must agree and commit to use effective medical methods of contraception for the entire duration of their participation in the study. Sexual abstinence will be accepted as an effective method of contraception for girls below 15 years of age.

• Ability to perform spirometry procedures in accordance with the American Thoracic Society guidelines (2005) for subjects =6 years old. Ability to perform peak expiratory flow (PEF) measurements for subjects =5 years old. Subjects <8 years of age who have documented inability to adequately perform spirometry can perform only the PEF evaluation. Subjects <5 years of age may be enrolled if they had no clinical features of moderate or severe persistent asthma severity (as defined by the 2007 National Heart, Lung, and Blood Institute [NHLBI] Guidelines) within 1 year before Visit 1.

• Subjects and/or parents/guardians willing to comply with all study requirements during participation in the study.

Exclusion Criteria:

• History of severe anaphylaxis to cow's milk resulting in hypotension, hypoxia or neurological compromise (collapse, loss of consciousness or incontinence) or requiring mechanical ventilation.

• Pregnancy or lactation.

• Spirometry forced expiratory volume in 1 second (FEV1) <80% of the predicted value at Visit 1 for subjects =6 years and able to perform the spirometry, or PEF <80% of predicted value at Visit 1 for subjects performing only the PEF measurements.

• Any clinical features of moderate or severe persistent asthma severity (as defined by the 2007 NHLBI guidelines) and high daily doses of inhaled corticosteroids.

• Known allergy to the Viaskin patch materials or excipients, or to any of the components of the food challenge formulas other than the cow's milk proteins.

• Allergy or known history of reaction to Tegaderm® medical dressing with no possibility to use an alternative adhesive dressing authorized by the sponsor in replacement.

• Subjects having objective symptoms to the placebo formula leading to stopping the challenge during the screening DBPCFC.

• Severe reaction during the screening DBPCFC defined as need for intubation, and/or hypotension persisting after epinephrine administration, and/or the need for >2 doses of epinephrine.

• Symptomatic allergy to pollens with symptoms during the pollen season that might interfere with the symptoms observed during the DBPCFC, if the DBPCFC is performed during the pollen season. Screening of such subjects should be made out of the pollen season.

• Inability to discontinue short-acting antihistamines for 3 days or long-acting antihistamines for 5 to 7 days (depending on the half-life) before the DBPCFC.

• Use of systemic long-acting corticosteroids within 12 weeks before Visit 1 and/or use of systemic short-acting corticosteroids within 4 weeks before Visit 1 or use of systemic long-acting or short-acting corticosteroids during screening (unless used to treat symptoms triggered by the DBPCFC or triggered by accidental allergen consumption; in the latter case DBPCFC must then be scheduled after a minimum of 7 wash-out days).

• Subjects with asthma conditions meeting 1 or several criteria below:

• Uncontrolled persistent asthma (as defined by the 2007 NHLBI guidelines) or subject being treated with a combination therapy of medium or high daily dose of inhaled corticosteroid with a long acting inhaled ß2-agonist. Intermittent asthmatic subjects who require intermittent use of inhaled corticosteroids for rescue are permitted.

• At least 2 systemic corticosteroid courses for asthma within 1 year before Visit 1 or 1 oral corticosteroid course for asthma within 3 months before Visit 1, or during screening (unless used to treat symptoms triggered by the DBPCFC).

• Prior intubation/mechanical ventilation due to asthma within 2 years before Visit 1, or during screening.

• Upper respiratory infection or gastroenteritis within 7 days of DBPCFC (DBPCFC must then be rescheduled at least 7 days after resolution of these conditions).

• Any history of milk immunotherapy (eg, oral immunotherapy, sublingual immunotherapy or specific oral tolerance induction).

• Prior history of any other food allergen immunotherapy (eg, oral immunotherapy, sublingual immunotherapy or specific oral tolerance induction) within 5 years before Visit 1.

• Subjects currently under aeroallergen immunotherapy and unwilling or unable to discontinue at the time of Visit 1. Aeroallergen Immunotherapy must be discontinued at the time of Visit 1.

• Use of any anti-IgE drug (eg, omalizumab), any immunomodulatory therapy, or any biological agent therapy (eg, anti-tumor necrosis factor drugs) within 1 year before Visit 1, or during screening.

• Generalized dermatologic diseases (eg, severe atopic dermatitis, uncontrolled generalized eczema, icthyosis vulgaris) with no intact zones to apply the Viaskin patch, or urticarial and mast cells disorders such as chronic idiopathic urticaria.

• Subject and/or subject's parents/guardians with obvious excessive anxiety and unlikely to cope with the conditions of a food challenge.

• Past or current disease, including but not limited to active eosinophilic gastrointestinal disorders, autoimmune disorders, immunodeficiency, malignancy, uncontrolled disease (hypertension, diabetes, psychiatric disorder, cardiac disease), or other disorders (eg, liver, gastrointestinal, kidney, cardiovascular, pulmonary disease or blood disorder) which in the opinion of the Investigator or the sponsor may affect the subject's participation in the study or place the subject at increased risk.

• Subjects and/or parents/guardians unable to use the epinephrine auto-injector properly in spite of being adequately trained.

• Contraindicated condition for the use of epinephrine.

• Use of any investigational drug or device, or participation in another interventional clinical study within 3 months before Visit 1.

• Subjects receiving beta-blockers or Angiotensin converting-enzyme (ACE) inhibitors.

• Subjects unable to follow the protocol requirements.

Related Conditions & MeSH terms

• Food Allergy
• Food Hypersensitivity
• Hypersensitivity
• Milk Hypersensitivity

Intervention

Biological:
• Viaskin Milk 150 mcg
Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
• Viaskin Milk 300 mcg
Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
• Viaskin Milk 500 mcg
Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
• Viaskin Placebo
Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.

Locations

Country	Name	City	State
Canada	Cheema Research Inc.	Mississauga	Ontario
Canada	Centre Hospitalier Universitaire Sainte Justine	Montréal	Quebec
Canada	Ottawa Allergy Research Corporation	Ottawa	Ontario
Canada	Clinique Spécialisée en allergie de la Capitale	Québec
Canada	Gordon Sussman Clinical Research Inc.	Toronto	Ontario
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Johns Hopkins Hospital	Baltimore	Maryland
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Children's Medical Center of Dallas	Dallas	Texas
United States	Arkansas Children's Hospital	Little Rock	Arkansas
United States	Mount Sinai Medical Center	New York	New York
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania
United States	Rady Children's Hospital	San Diego	California
United States	ASTHMA, Inc.	Seattle	Washington
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
DBV Technologies

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy endpoint will be the percentage (%) of subjects who are treatment responders after 12 months of EPIT treatment.	A treatment responder is defined as a subject who meets at least one of the following criteria: A =10-fold increase in the Cumulative Reactive Dose (CRD) of cow's milk proteins at the Month 12 double-blind placebo-controlled food challenge (DBPCFC) as compared to baseline value and reaching at least 144 mg of cow's milk proteins; A CRD of cow's milk proteins =1444 mg at the Month 12 DBPCFC.	From baseline to Month 12.
Secondary	Mean and median CRD of cow's milk proteins.		From baseline to Month 12
Secondary	Change in levels of sIgE and sIgG4 to cow's milk.		From baseline to Week 3, Month 3, Month 6, Month 12
Secondary	Change in levels of sIgE and sIgG4 to caseins, a-lactalbumin and ß-lactoglobulin		From baseline to Week 3, Month 3, Month 6, Month 12
Secondary	Change in Skin Prick Test wheal.		From baseline to Month 3, Month 6, Month 12
Secondary	Change in the severity of symptoms elicited during the milk DBPCFC.		From baseline to Month 12
Secondary	Change in Quality of Life (QoL) assessments.		From baseline to Month 12
Secondary	Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)		Up to 6 years
Secondary	Percentage of subjects who are treatment responders over the course of the open-label treatment period.		Up to 5 years in the open-label treatment period
Secondary	CRD of cow's milk protein over the course of the open-label treatment period		Up to 5 years in the open-label treatment period